Since its foundation in 2016, WellmarkerBio("WMBIO") has been developing 9 predictive-biomarker driven first-in-class anticancer pipelines.

With predictive biomarkers, development programs with trials employing patient preselection biomarkers are said to have three-fold higher LOA by the FDA and could reduce the cost and the risk of administrating ineffective drugs to the patients.

Over the past 5 years, WMBIO made outstanding operation progress, marked by the advancement of WM-S1-030 in the phase 1a clinical study and progression of WM-A1 preclinical program. The company has raised a total of $55 million closing series C round in August 2021 and completed 3 KDDF government projects successfully. Accredited by the Ministry of Science and ICT of Korea(MIST) as an ‘Excellent Corporation R&D Center’ and acquiring Inno-Biz certification by the Ministry of SMEs and Startups(a certification conferred to SMEs equipped with competitive edge based on the company’s innovate technology), WMBIO is rapidly advancing its robust pipeline of early stage assets.

“2022 is going to be a vital year for WellmarkerBio to set in motion an ambitious-yet-achievable plan of developing a blockbuster drug” said, Dong-Hoon Jin, CEO of Wellmarker Bio. “We are planning to submit the application for preliminary review in mid-2022. After the IPO, our priority is to execute on our strategy aimed at out-licensing 2-3 candidate pipelines to global top pharmaceuticals and develop a portfolio of clinical-stage products that could address significant unmet medical need in oncology” he added.

M&A is also on the list of WMBIO’s business plan. To reinforce core technology and strengthen manpower, Wellmarker is considering to geographically expand, advance new discoveries through collaborations with leading companies and institutions worldwide.

“We believe we are well-positioned to realize our mission of becoming a global pharmaceutical company and advance precision medicines by positively impacting many patients through our competitive edge”.